FrontlineTherapy

(25:27)

Frontline Therapy Advances for Multiple Myeloma Patients | ASH 2024 Insights for Patients

(3:8)

Maintenance and Frontline Therapy in CLL

(5:26)

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion

(1:55)

How frontline therapy impacts the management of patients with ALL prior to CAR-T

(1:9)

Frontline Therapy in Melanoma

(3:50)

Daratumumab-based frontline therapy in AL amyloidosis: real-world Mayo Clinic experience

(3:7)

The Uromigos: Frontline Therapy in RCC

(42:6)

How to choose the frontline therapy in metastatic All-wild NSCLC

(27:23)

Tian Zhang on Frontline Therapy in RCC

(1:49)

Frontline therapy updates for myeloma patients from ASH 2024!

(40)

Brentuximab vedotin-nivolumab alone and then with R-CHP as frontline therapy for PMBCL

(4:22)

Choosing Frontline Therapy for Mantle Cell Lymphoma

(5:42)

Frontline Therapy

(31:32)

Frontline Therapy for Polycythemia Vera

(5:54)

Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?

(5:56)

mCRC: Best Approaches to Frontline Therapy

(5:51)

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

(54)

Frontline therapy for multiple myeloma

(1:27)